Search Results - "Pluzanski, Adam"

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study.

Authors: Pluzanski, Adam Bryl, Maciej Chmielewska, Izabela et al.

Source: Cancers. Mar2023, Vol. 15 Issue 5, p1581. 12p.

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).

Authors: Janzic, Urska Maimon Rabinovich, Natalie Shalata, Walid et al.

Source: Current Oncology. Aug2024, Vol. 31 Issue 8, p4369-4381. 13p.

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Authors: Mok, Tony S. Cheng, Ying Zhou, Xiangdong et al.

Source: Drugs. Feb2021, Vol. 81 Issue 2, p257-266.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Authors: Buckley, Hannah L. Collinson, Fiona J. Ainsworth, Gemma et al.

Source: BMC Cancer. 11/14/2019, Vol. 19 Issue 1, p1-9. 9p. 1 Diagram.

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Authors: Janžič, Urška Turnšek, Nina Dediu, Mircea et al.

Source: Current Oncology. Aug2022, Vol. 29 Issue 8, p5833-5845. 13p. 2 Charts, 2 Graphs.

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.

Authors: Agbarya, Abed Shalata, Walid Addeo, Alfredo et al.

Source: Journal of Clinical Medicine. Mar2022, Vol. 11 Issue 6, p1738-N.PAG. 16p.

Combining Life and Health Insurance.

Authors: Koijen, Ralph S J Nieuwerburgh, Stijn Van

Source: Quarterly Journal of Economics. May2020, Vol. 135 Issue 2, p913-958. 46p. 6 Charts.

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.

Authors: Wang, Dongxu Lin, Jianzhen Yang, Xu et al.

Source: Journal of Hematology & Oncology. 4/24/2019, Vol. 12 Issue 1, pN.PAG-N.PAG. 1p.

Jingfukang induces anti-cancer activity through oxidative stress-mediated DNA damage in circulating human lung cancer cells.

Authors: Que Z Zhou Z Luo B et al.

Source: BMC complementary and alternative medicine [BMC Complement Altern Med] 2019 Aug 07; Vol. 19 (1), pp. 204. Date of Electronic Publication: 2019 Aug 07.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101088661 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6882 (Electronic) Linking ISSN: 14726882 NLM ISO Abbreviation: BMC Complement Altern Med Subsets: MEDLINE

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.

Authors: Jafarnejad M Gong C Gabrielson E et al.

Source: The AAPS journal [AAPS J] 2019 Jun 24; Vol. 21 (5), pp. 79. Date of Electronic Publication: 2019 Jun 24.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE